Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Active not recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1

Conditions

Neurotoxicity Syndromes 1Hematologic Neoplasms 1Delirium 1

Interventions

Paclitaxel 7Oxaliplatin 6Vincristine 4Radiotherapy 4Leucovorin 4Carboplatin 4Amifostine 4Taxes 3Sodium Chloride 3Procarbazine 3Methotrexate 3Fluorouracil 3Cytarabine 3xaliproden 2glucarpidase 2Rituximab 2Radiotherapy, Intensity-Modulated 2Radiotherapy, Conformal 2Prednisolone 2Magnesium Sulfate 2Duloxetine Hydrochloride 2Dexamethasone 2Cyclophosphamide 2Cisplatin 2Calcium Gluconate 2Acupuncture Therapy 2neurotropin 1motexafin gadolinium 1haloperidol decanoate 1glutamic acid diethyl ester 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Interventional × Neurotoxicity Syndromes × haloperidol decanoate × Clear all
NCT01949662 2026-02-13

Haloperidol and Lorazepam for Delirium in Patients With Advanced Cancer

M.D. Anderson Cancer Center

Phase 2 Active not recruiting
93 enrolled 14 charts
Other hematologic neoplasm

Delirium, Hematologic Neoplasms, Neurotoxicity Syndromes

Data powered by HemOnc (CC BY 4.0) Colophon âš¡